# MOTS-c in a muscle that cannot move

> MOTS-c and muscle | Vital Force Peptides — MOTS-c at Vital Force Peptides: CK2, muscle wasting during immobilisation, running and grip in mice, plus the unanswered human safety questions.

**MOTS-c**

The disuse experiment and the running mice raise separate questions: retaining muscle and improving performance.

## CK2 activity

A muscle deprived of movement is a demanding place to test a metabolic idea. In the [CK2 study](https://pubmed.ncbi.nlm.nih.gov/39559755/), MOTS-c reduced immobilisation-related muscle wasting in mice and increased muscle glucose uptake. Cell-free experiments showed direct binding to CK2, a protein involved in controlling cellular activity.

The response varied by tissue: CK2 activity rose in muscle and fell in fat. The tissue split makes a blanket claim about switching metabolism on seem especially clumsy to me. The study proposes a specific target and shows that the same target can respond differently around the body. It establishes an animal and laboratory mechanism; a treatment for people losing muscle during inactivity remains to be demonstrated.

## The treadmill and the grip test

The [exercise and ageing study](https://pubmed.ncbi.nlm.nih.gov/33473109/) examined young, middle-aged and old mice. Exercise increased their naturally produced MOTS-c. Giving extra improved physical performance, including treadmill running, grip strength and gait; the older mice’s running result was statistically significant.

Running, gripping and walking give this experiment more texture than a single claim about energy. Those endpoints earn my enthusiasm: the animals had tasks to perform. Calling MOTS-c an exercise mimetic means it is being investigated for effects resembling some responses to exercise. The evidence here reaches mice. It leaves human endurance, strength, weight loss and longevity benefits unestablished.

![A white mouse walks on a small enclosed laboratory treadmill.](images/mots-c-treadmill.webp)

*Editorial illustration of a mouse treadmill. The performance findings discussed here came from mouse experiments.*

## Mitochondria and the nucleus

MOTS-c is encoded in mitochondrial DNA, in the region called 12S rRNA. Mitochondria are the cell structures closely involved in making usable energy from food. The [review of MOTS-c biology](https://pubmed.ncbi.nlm.nih.gov/36670507/) describes findings from cell experiments on folate metabolism and AMPK, a protein that senses the cell’s fuel supply. Those processes help explain why muscle became such an important experimental target.

In [human and mouse cells grown in dishes](https://pubmed.ncbi.nlm.nih.gov/29983246/), nutrient restriction or damage sent MOTS-c into the nucleus, where most of the cell’s genetic instructions are housed. It altered activity around genes involved in stress responses and metabolism. The journey from a mitochondrial origin to the nucleus fascinates me. The experiment measured cell behaviour under stress; it did not measure a person’s alertness.

## The people whose blood was measured

The human evidence takes a different form. A [cohort of 94 people receiving chronic haemodialysis](https://pubmed.ncbi.nlm.nih.gov/39111290/) had naturally circulating MOTS-c measured and was followed for a median of 26.5 months. Higher levels were associated with greater risk of death or non-fatal cardiovascular events, and the measurement modestly improved risk prediction. Nobody was given MOTS-c as treatment.

That setting deserves to stay visible. Severe kidney disease changes the question being asked; a blood association in that population cannot tell us the consequences of giving MOTS-c to someone else. Small studies, differences in ancestry and genetic variants, and mechanisms awaiting independent replication add further uncertainty.

## Safety; sport restrictions

There is no established human pharmacokinetic profile here: how extra MOTS-c is absorbed, distributed and cleared, or how effects change with amount. Completed human efficacy trials are absent from this evidence base. That leaves adverse effects and long-term risks poorly characterised. A reassuring human safety list would require evidence missing from the animal work.

MOTS-c lacks FDA approval for human use. Research preparations have uncertain identity, purity and sterility, and elite sport restricts MOTS-c use. The animal findings supply reasons to investigate muscle function further. They supply no validated human injection routine. [Approval and handling questions](/faq) are addressed separately.

---

Vital Force Peptides is an independent digest of metabolic signals and measured weight outcomes, not a clinic, vendor, or source of medical direction.